Bulk Pharmaceutical API Sources for DEXTROSE 20% IN PLASTIC CONTAINER

Bulk Pharmaceutical API Sources for DEXTROSE 20% IN PLASTIC CONTAINER

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		66370
IS Chemical Technology		I14-6963
ABI Chem		AC1L2586
AKos Consulting & Solutions		AKOS015915125

Dextrose 20% in Plastic Container API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the global supply chain for Bulk Active Pharmaceutical Ingredient (API) sources used in the manufacturing of Dextrose 20% in Plastic Container. Key manufacturers, geographic concentrations, and patent landscapes are examined to inform strategic sourcing and R&D decisions.

What are the primary global manufacturers of Dextrose API?

The production of dextrose, a monosaccharide sugar derived from starch, is a mature and globally distributed industry. Manufacturers typically leverage corn or other starch-rich agricultural products as primary raw materials. The API itself, anhydrous dextrose (also known as D-glucose), is characterized by a purity exceeding 99.5% for pharmaceutical applications.

Key global manufacturers of pharmaceutical-grade dextrose API include:

• Cargill, Inc. (United States): A significant producer with a broad portfolio of corn-derived ingredients, including pharmaceutical-grade dextrose. Cargill operates multiple manufacturing facilities globally.
• ADM (Archer Daniels Midland Company) (United States): Another major agricultural processor with substantial dextrose production capacity. ADM's operations are geographically diversified.
• Roquette Frères (France): A leading global player in plant-based ingredients, Roquette is a significant supplier of dextrose for pharmaceutical and food industries. They operate manufacturing sites across Europe, North America, and Asia.
• Ingredion Incorporated (United States): Ingredion processes corn and other starches into a range of ingredients, including dextrose. Their global footprint supports widespread supply.
• Tereos (France): A cooperative sugar and starch group, Tereos is a substantial European producer of dextrose for various industrial uses, including pharmaceuticals.
• Agrana Beteiligungs-AG (Austria): Agrana operates starch facilities in Central and Eastern Europe, producing dextrose for food and pharmaceutical applications.

These companies often produce dextrose at scale, with dedicated lines for pharmaceutical-grade material that adheres to stringent pharmacopoeial standards, such as USP (United States Pharmacopeia) and EP (European Pharmacopoeia).

What is the patent landscape surrounding dextrose production and formulation?

The patent landscape for dextrose production itself is largely characterized by historical, foundational patents that have long since expired. The fundamental chemical processes for producing and purifying dextrose from starch are well-established and in the public domain.

However, innovation and patentable subject matter exist in several related areas:

• Novel Purification Techniques: While the core process is public, patents may cover specific, proprietary methods for achieving exceptionally high purity levels or removing specific trace impurities. These often involve advanced filtration, crystallization, or chromatographic techniques.
• Enzymatic Conversion Processes: Advances in biocatalysis have led to patents for improved enzymatic methods for starch hydrolysis and dextrose production, potentially offering greater efficiency, yield, or reduced environmental impact compared to traditional acid hydrolysis.
• Crystalline Forms and Polymorphism: Patents can be granted for specific crystalline forms (polymorphs) of dextrose that exhibit advantageous properties, such as improved stability, solubility, or handling characteristics relevant to API manufacturing.
• Combination Products and Formulations: The most active area of patenting related to dextrose in solution is in its use as a diluent or carrier in intravenous (IV) formulations. Patents here do not cover dextrose itself but rather:
  • Novel IV Solution Compositions: Combinations of dextrose with other active pharmaceutical ingredients (APIs), electrolytes, or excipients for specific therapeutic indications. For example, patents might claim a new IV formulation for sepsis management that includes a specific concentration of dextrose alongside antimicrobial agents and buffering agents.
  • Stabilization Methods for Sensitive APIs: Dextrose solutions can serve as a stable vehicle for certain otherwise unstable drugs. Patents might cover specific dextrose concentrations and pH ranges that optimize the stability of a particular API in an IV solution.
  • Delivery Devices and Methods: Patents could relate to specialized plastic containers designed for dextrose solutions, focusing on material science, barrier properties, or compatibility with specific administration sets, though this is more in the realm of drug-device combination products.
  • Manufacturing Processes for Formulated Products: While not the API itself, patents may protect specific methods for sterile manufacturing, filling, and sealing of dextrose-containing IV bags, especially if novel sterilization techniques or process controls are employed.

Example of a patent focus: A patent might claim "A sterile, ready-to-use parenteral solution comprising D-glucose at a concentration of 20% (w/v), water for injection, and [specific electrolyte or buffer salt] for the treatment of [specific medical condition]." The patent would likely detail the specific ranges for concentrations, pH, and methods of preparation to ensure sterility and efficacy.

The vast majority of patents related to Dextrose 20% in Plastic Container will focus on the specific IV formulation and its intended therapeutic use, rather than the fundamental production of the dextrose API.

Which regions dominate the production of pharmaceutical-grade dextrose API?

The production of pharmaceutical-grade dextrose API is primarily concentrated in regions with a strong agricultural base, particularly for corn and other starch sources, and well-established industrial chemical manufacturing infrastructure.

Key dominating regions include:

• North America (United States and Canada): The U.S. is a global leader due to its vast corn production and sophisticated bioprocessing industries. Major players like Cargill, ADM, and Ingredion have significant API manufacturing capacity within the region. Canada also contributes through its own agricultural and industrial capabilities.
• Europe: Western European countries, particularly France, Germany, and Austria, have a strong presence. Companies like Roquette and Tereos are significant European producers. These regions benefit from advanced manufacturing technologies and stringent quality control standards.
• Asia-Pacific (China and India): China has emerged as a substantial global supplier for various APIs, including dextrose. Its large industrial base and competitive manufacturing costs have made it a significant source. India, while more prominent in small-molecule API production for generics, also has dextrose manufacturing capabilities that contribute to global supply.

The dominance of these regions is driven by:

• Raw Material Availability: Proximity to corn belts and other starch-rich crop production is critical for cost-effective dextrose manufacturing.
• Technological Expertise: Advanced bioprocessing, fermentation, and purification technologies are essential for producing pharmaceutical-grade API.
• Regulatory Infrastructure: Regions with robust regulatory frameworks (FDA, EMA) ensure that manufacturing facilities meet the necessary Good Manufacturing Practices (GMP) and quality standards.
• Established Chemical Industry: A mature chemical manufacturing sector facilitates the complex processes involved in API production.

Geographic diversification of sourcing is crucial for pharmaceutical manufacturers to mitigate supply chain risks, including geopolitical instability, natural disasters, and trade disruptions.

What are the key specifications and quality standards for Dextrose 20% API?

Pharmaceutical-grade dextrose API must meet rigorous specifications to ensure its safety, efficacy, and suitability for parenteral administration. These standards are defined by major pharmacopoeias.

The primary pharmacopoeial standards are:

• United States Pharmacopeia (USP):

  • Assay: Not less than 99.0% and not more than 101.0% of C6H12O6, calculated on the anhydrous basis.
  • Identification: Conforms to tests for D-glucose.
  • Loss on Drying: Not more than 0.5% (for anhydrous dextrose).
  • Residue on Ignition: Not more than 0.1%.
  • Heavy Metals: Not more than 5 ppm.
  • Chloride: Not more than 0.02%.
  • Sulfate: Not more than 0.02%.
  • Acidity: Not more than 0.2 mL of 0.1 N NaOH.
  • Bacterial Endotoxins: Meets specified limits for parenteral products (e.g., typically less than 0.25 EU/mg for bulk API intended for injection, with final product release testing being more critical).
  • Sterility: If supplied as sterile API, must comply with sterility testing. However, it is often supplied as non-sterile and sterilized during the final product manufacturing.

• European Pharmacopoeia (EP):

  • Definition: Anhydrous D-glucose.
  • Characterisation: White crystalline powder or colourless crystals.
  • Identification: Confirms to tests for D-glucose.
  • Appearance of Solution: A 10% solution in water is clear and colourless.
  • Specific Optical Rotation: [α]D^20 between +52.7° and +53.3°.
  • Loss on Drying: Not more than 0.5%.
  • Sulphated Ash: Not more than 0.1%.
  • Related Substances: Limits for specific impurities such as fructose, xylose, and other sugars.
  • Heavy Metals: Not more than 5 ppm.
  • Chloride: Not more than 100 ppm.
  • Sulfate: Not more than 150 ppm.
  • Bacterial Endotoxins: Meets specified limits.

• Other Pharmacopoeias (e.g., JP - Japanese Pharmacopoeia): While generally aligned, minor variations in impurity profiles or testing methods may exist. Manufacturers typically aim to meet the most stringent requirements of the markets they serve.

Key Considerations for Sourcing:

• Source of Raw Material: The agricultural origin of the starch (e.g., corn, wheat) can influence trace impurity profiles.
• Manufacturing Process: Acid hydrolysis vs. enzymatic hydrolysis can result in different impurity profiles.
• Particle Size and Morphology: Relevant for dissolution rates and handling during formulation.
• Stability: Dextrose is susceptible to degradation, especially under heat and in the presence of impurities. Long-term stability data is crucial.
• GMP Compliance: All API must be manufactured in facilities adhering to current Good Manufacturing Practices (cGMP). Regular audits and quality agreements with suppliers are essential.

The "20%" in "Dextrose 20% in Plastic Container" refers to the concentration of dextrose in the final sterile solution (w/v), not a specification of the API itself. The API is typically supplied as anhydrous dextrose, and the concentration is achieved by dissolving the API in Water for Injection (WFI) during the formulation process.

What are the major supply chain risks and mitigation strategies for Dextrose API?

The supply chain for dextrose API, while relatively mature, faces several risks that can impact availability and cost.

Major Supply Chain Risks:

• Agricultural Volatility:

  • Crop Yields: Dextrose is derived from agricultural commodities like corn. Fluctuations in crop yields due to weather events (droughts, floods), pests, or diseases can impact raw material availability and price.
  • Commodity Price Swings: Global demand for corn (for food, feed, and biofuels) can significantly influence its price, directly affecting dextrose production costs.
  • Geopolitical Factors: Trade disputes, export/import restrictions on agricultural products can disrupt supply lines.

• Manufacturing Disruptions:

  • Facility Issues: Equipment failures, natural disasters affecting manufacturing plants, or accidents can lead to production downtime.
  • Labor Shortages: Availability of skilled labor in chemical manufacturing can be a challenge.
  • Regulatory Changes: Stricter environmental regulations or updated GMP requirements can necessitate costly process modifications or plant closures.

• Logistical Challenges:

  • Transportation Costs: Fluctuations in fuel prices and shipping capacity can increase the cost and lead time of API delivery.
  • Port Congestion and Shipping Delays: Global trade disruptions can cause significant delays in receiving raw materials or shipping finished API.
  • Warehousing and Storage: Maintaining adequate and compliant storage conditions for API is critical.

• Quality and Compliance Issues:

  • Supplier Non-Compliance: A supplier failing to meet GMP standards or pharmacopoeial requirements can lead to batch rejections, recalls, and severe regulatory scrutiny.
  • Counterfeit APIs: While less common for high-volume commodities like dextrose, the risk of substandard or counterfeit APIs entering the supply chain exists.
  • Impurity Profile Changes: Unforeseen changes in the API's impurity profile, even if within pharmacopoeial limits, can impact the stability or performance of the final drug product.

• Demand Surges:

  • Pandemic-Related Demand: As a critical component of IV fluids, demand for dextrose surged significantly during global health crises, straining existing production and distribution networks.
  • Increased Use in Formulations: Broader adoption of dextrose-containing IV solutions for various therapeutic areas can lead to unexpected demand increases.

Mitigation Strategies:

• Diversified Sourcing:

  • Multiple Suppliers: Engage with a minimum of two to three qualified API manufacturers across different geographic regions to avoid over-reliance on a single source.
  • Dual-Sourcing of Raw Materials: If feasible, work with suppliers who have diversified raw material sources.

• Strategic Inventory Management:

  • Safety Stock: Maintain adequate safety stock of critical API to buffer against short-term supply disruptions. This requires careful forecasting and balancing inventory holding costs against supply risk.
  • Consignment Stock: Explore consignment agreements with key suppliers to ensure availability without immediate capital outlay.

• Robust Supplier Qualification and Auditing:

  • Rigorous Due Diligence: Conduct thorough audits of potential suppliers, including their cGMP compliance, quality management systems, and financial stability.
  • Regular Audits: Perform periodic re-audits of existing suppliers to ensure ongoing compliance.
  • Quality Agreements: Establish comprehensive quality agreements detailing responsibilities, change control, and issue resolution.

• Contractual Safeguards:

  • Long-Term Contracts: Negotiate long-term supply agreements with price escalation clauses tied to objective indices (e.g., commodity prices, inflation) to provide cost stability.
  • Force Majeure Clauses: Clearly define force majeure events and outline mutual obligations during such occurrences.
  • Lead Time Guarantees: Secure commitments on maximum lead times.

• Enhanced Supply Chain Visibility:

  • Real-time Tracking: Implement systems for real-time tracking of shipments from the manufacturing site to the formulation facility.
  • Data Analytics: Utilize data analytics to monitor supplier performance, identify potential risks, and forecast demand more accurately.

• Geographic Diversification:

  • Regional Hubs: Establish manufacturing or warehousing facilities in different geographic regions to serve local markets and reduce reliance on long-haul transportation.

• Contingency Planning:

  • Business Continuity Plans: Develop and regularly test business continuity plans that outline alternative sourcing and production strategies in case of major disruptions.
  • Scenario Planning: Conduct scenario planning exercises to prepare for various potential disruptions (e.g., a major supplier bankruptcy, a pandemic resurgence).

By implementing a multi-faceted approach to risk management, pharmaceutical companies can build more resilient supply chains for essential APIs like dextrose.

---

Key Takeaways

• Dextrose API is produced by a global network of large agricultural processors and chemical manufacturers, primarily located in North America, Europe, and Asia.
• The patent landscape for dextrose API production is mature; innovation is concentrated in advanced purification, enzymatic processes, crystalline forms, and combination IV formulations.
• Dextrose API must meet stringent pharmacopoeial standards (USP, EP) for purity, identity, and low levels of impurities and endotoxins.
• Key supply chain risks include agricultural volatility, manufacturing disruptions, logistical challenges, and quality control failures, necessitating diversified sourcing, strategic inventory, robust supplier qualification, and contingency planning.

---

Frequently Asked Questions

1. Are there significant differences in the quality of dextrose API from different geographic regions? Quality is primarily determined by adherence to pharmacopoeial standards (USP, EP, JP) and cGMP. While regional manufacturing strengths exist, reputable suppliers worldwide can produce API meeting these stringent requirements. The key is rigorous supplier qualification and ongoing quality monitoring, not the region of origin alone.

2. Can dextrose API be supplied in a sterile form, or is it always non-sterile requiring sterilization during formulation? Dextrose API can be supplied in both non-sterile and sterile forms. However, it is commonly supplied as non-sterile and then subjected to terminal sterilization (e.g., autoclaving) during the final product manufacturing process of the Dextrose 20% in Plastic Container to ensure sterility of the final infused product.

3. What is the typical shelf life of pharmaceutical-grade dextrose API? Pharmaceutical-grade dextrose API, when stored under recommended conditions (typically cool, dry, and protected from light), generally has a shelf life of 2 to 5 years. Specific shelf life data should be obtained from the API manufacturer and confirmed through stability studies.

4. How does the price of dextrose API fluctuate, and what are the main drivers? Dextrose API pricing is heavily influenced by the cost of its primary agricultural feedstock, predominantly corn. Factors like global corn supply and demand, energy prices (affecting processing and transportation), currency exchange rates, and overall market demand for IV fluids significantly impact pricing.

5. What are the critical factors to consider when qualifying a new supplier for dextrose API? Critical factors include verification of cGMP compliance through audits, robust quality management systems, a documented history of reliable supply, pharmacopoeial adherence (USP/EP/JP), impurity profiling, financial stability, and the supplier's capacity and flexibility to meet demand.

---

Citations

[1] United States Pharmacopeia. (2023). United States Pharmacopeia and National Formulary (USP-NF). U.S. Pharmacopeial Convention.

[2] European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (Ph. Eur.). Council of Europe.